Onglyza and Sepsis - a phase IV clinical study of FDA data

Summary:

Sepsis is reported as a side effect among people who take Onglyza (saxagliptin hydrochloride), especially for people who are male, 60+ old, have been taking the drug for 6 - 12 months also take Metformin, and have High blood pressure.

The phase IV clinical study analyzes which people have Sepsis when taking Onglyza. It is created by eHealthMe based on reports of 8,520 people who have side effects when taking Onglyza from the FDA, and is updated regularly.

What is Onglyza?

Onglyza has active ingredients of saxagliptin hydrochloride. It is often used in diabetes. eHealthMe is studying from 8,638 Onglyza users. Check the latest studies of Onglyza.

What is Sepsis?

Sepsis (a severe blood infection that can lead to organ failure and death) is found to be associated with 2,525 drugs and 3,260 conditions by eHealthMe. Check the latest studies of Sepsis.

On Aug, 06, 2026

8,520 people reported to have side effects when taking Onglyza.
Among them, 52 people (0.61%) have Sepsis.

Among these 52 people:

How long have people been on Onglyza when they have Sepsis? *

What is the gender of people who have Sepsis when taking Onglyza? *

female: 42 %
male: 58 %

What is the age of people who have Sepsis when taking Onglyza? *

What are other drugs people take besides Onglyza? *

What are other side effects people have besides Sepsis? *

Pneumonia: 10 people, 19.23%
Diarrhea: 7 people, 13.46%
Urinary Tract Infection: 7 people, 13.46%
Haemoglobin Decreased: 5 people, 9.62%
Adrenal Insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids): 5 people, 9.62%
Headache (pain in head): 5 people, 9.62%
Dehydration (dryness resulting from the removal of water): 4 people, 7.69%
Spontaneous Haematoma (blood collection with medical reason): 4 people, 7.69%
Small Intestinal Obstruction (blockage in small intestine): 4 people, 7.69%
Shock Haemorrhagic (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin due to excess bleeding): 4 people, 7.69%

What are the existing conditions these people have? *

High Blood Pressure: 9 people, 17.31%
High Blood Cholesterol: 4 people, 7.69%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 4 people, 7.69%
Cardiomyopathy (weakening of the heart muscle): 3 people, 5.77%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 5.77%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 5.77%
Depression: 3 people, 5.77%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 3 people, 5.77%
Hypertriglyceridaemia (excess of triglycerides in the blood): 3 people, 5.77%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 2 people, 3.85%

* Approximation only. Some reports may have incomplete information.

Do you take Onglyza and have Sepsis?

- Check whether Sepsis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Onglyza:

Onglyza (8,638 reports)

Sepsis treatments and more:

Sepsis (140,102 reports)

Browse all side effects of Onglyza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Sepsis:

Sepsis (2,525 drugs)

Browse all the conditions that are associated with Sepsis:

Sepsis (3,260 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on saxagliptin hydrochloride (the active ingredients of Onglyza) and Onglyza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.